Open Nav

RubrYc Therapeutics, Inc.

  • Isaac Bright, RubrYc Therapeutics, Inc.

Preview $50M Series B Financing anticipated 2019

  • Date:Wednesday, October 17
  • Time:2:30 PM - 2:45 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Though early discovery R&D activities produce millions of potential drug candidates, gold-standard analytical methods and tools can not keep pace. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path to information-driven discovery of therapeutic antibodies, and related therapies. Using the RubrYc Discovery Engine, the Company can decode protein interactions through the integration of predictive analytics and biological measurements. This interface-targeted approach allows RubrYc to accelerate pre-clinical therapeutic antibody discovery, while minimizing many of the risks of industry-standard early-stage R&D. Founded in 2017, RubrYc Therapeutics, Inc. emerged as the exclusive biotherapeutic partner of immunomics leader HealthTell. In April, 2018, RubrYc Therapeutics spun out of HealthTell to define its trailblazing role mining protein:protein interfaces to build better therapies.
  • Company
  • Company HQ City:San Ramon
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Isaac J. Bright, MD
  • Year Founded:2017
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development :RTX-001 is a novel T-Cell Checkpoint Inhibitor for Oncology applications
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :4
  • Previous and Current Investors:Third Point; Paladin; Vital Ventures
  • Size of Last Investment Round:$10M
  • Total Amount Raised to Date, In All Rounds:$8.6M
Isaac Bright
RubrYc Therapeutics, Inc.